Fondazione Policlinico Tor Vergata Trials

Fondazione Policlinico Tor Vergata	Welcome, Profile Billing Logout

29 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

VENDITTI, Adriano

AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting

172

Europe

Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD

Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia With FLT3/ITD Mutation

12/22

08/25

NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting

414

Europe

Gemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.

Acute Myeloid Leukemia

04/25

04/27

NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting

322

Europe, Canada, US

Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF

Arog Pharmaceuticals, Inc.

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

10/24

IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Recruiting

339

Europe, RoW

High intensity therapies, Low intensity therapies

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX

Acute Myeloid Leukemia, Relapse/Recurrence

01/28

RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting

Europe

RVU120, SEL120, Venetoclax

Ryvu Therapeutics SA

Acute Myeloid Leukemia

02/26

09/26

RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Active, not recruiting

Europe

RVU120, SEL120

Ryvu Therapeutics SA

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome

02/26

09/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting

N/A

104

Europe

Venetoclax plus HMA

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

12/22

12/23

IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting

N/A

4000

Europe

Registration into the STREAM platform

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/32

Maurillo, Luca

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting

N/A

343

Europe, RoW

Questionnaire

Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC

Acute Myeloid Leukemia

06/21

12/22

BOTTON, StÃ©phane DE

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting

Europe

Ponatinib, Azacitidine

Versailles Hospital

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

12/23

12/24

ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting

210

Europe

Cytarabine and Idarubicin, CPX-315

Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association

Acute Myeloid Leukemia

10/27

Torregrosa, Jose Mi

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Rejto, Laszlo

MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

	Jan 2024 - Dec 2024: Approval for myelofibrosis
	Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
	Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
	Feb 2024 - Feb 2024: Completion of P2b trial for JIA
	Feb 2024 - Feb 2024: Exclusivity expiry in US

Active, not recruiting

430

Europe, Canada, US, RoW

Pelabresib, Ruxolitinib, Placebo

Constellation Pharmaceuticals

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

08/23

12/27

BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

05/25

08/26

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting

504

Europe, Canada, US, RoW

Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone

Acrotech Biopharma Inc.

Peripheral T Cell Lymphoma

07/30

11/30

NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting

1/2

122

Europe, US, RoW

Vodobatinib (K0706) capsules

Sun Pharma Advanced Research Company Limited

Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)

08/26

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Sbraccia, Paolo

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting

N/A

100

Europe, US

Metreleptin

Aegerion Pharmaceuticals, Inc.

Generalised Lipodystrophy, Partial Lipodystrophy

10/31

ECLip Registry, NCT03553420: Registry for Patients With Lipodystrophy

Recruiting

N/A

5000

Europe, RoW

University of Ulm, Sorbonne University, University Hospital, Lille, University of Cambridge, Endocrinology Research Centre, Moscow, University of Leipzig, University of Amsterdam, Dokuz Eylul University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Rome Tor Vergata, University of Pisa, University of Santiago de Compostela, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University Hospital Muenster, Szeged University, Centro Hospitalar do Porto, University Medical Centre Ljubljana, Medical University of Vienna, Ostschweizer Kinderspital

Lipodystrophy Acquired, Lipodystrophy Congenital

01/68

D'Angelillo, Rolando Maria

NCT05071105: SBRT in Early Breast Cancer in Elderly Women

Recruiting

N/A

Europe

Stereotactic Body Radiation Therapy, SBRT, Stereotaxis, Stereotactic Radiotherapy

University of Rome Tor Vergata

Breast Neoplasm Female

11/23

Cedrone, Laura

NCT05071105: SBRT in Early Breast Cancer in Elderly Women

Recruiting

N/A

Europe

Stereotactic Body Radiation Therapy, SBRT, Stereotaxis, Stereotactic Radiotherapy

University of Rome Tor Vergata

Breast Neoplasm Female

11/23

Bennane, Louiza

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

VENDITTI, Adriano

AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting

172

Europe

Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD

Acute Myeloid Leukemia With FLT3/ITD Mutation

12/22

08/25

NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting

414

Europe

Gemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.

Acute Myeloid Leukemia

04/25

04/27

NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting

322

Europe, Canada, US

Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF

Arog Pharmaceuticals, Inc.

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

10/24

IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Recruiting

339

Europe, RoW

High intensity therapies, Low intensity therapies

Acute Myeloid Leukemia, Relapse/Recurrence

01/28

RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting

Europe

RVU120, SEL120, Venetoclax

Ryvu Therapeutics SA

Acute Myeloid Leukemia

02/26

09/26

RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Active, not recruiting

Europe

RVU120, SEL120

Ryvu Therapeutics SA

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome

02/26

09/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

Recruiting

N/A

104

Europe

Venetoclax plus HMA

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

12/22

12/23

IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting

N/A

4000

Europe

Registration into the STREAM platform

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/32

Maurillo, Luca

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting

N/A

343

Europe, RoW

Questionnaire

Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC

Acute Myeloid Leukemia

06/21

12/22

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting

Europe

Ponatinib, Azacitidine

Versailles Hospital

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

12/23

12/24

ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting

210

Europe

Cytarabine and Idarubicin, CPX-315

Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association

Acute Myeloid Leukemia

10/27

Torregrosa, Jose Mi

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Rejto, Laszlo

MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

	Jan 2024 - Dec 2024: Approval for myelofibrosis
	Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
	Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
	Feb 2024 - Feb 2024: Completion of P2b trial for JIA
	Feb 2024 - Feb 2024: Exclusivity expiry in US

Active, not recruiting

430

Europe, Canada, US, RoW

Pelabresib, Ruxolitinib, Placebo

Constellation Pharmaceuticals

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

08/23

12/27

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

05/25

08/26

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting

504

Europe, Canada, US, RoW

Acrotech Biopharma Inc.

Peripheral T Cell Lymphoma

07/30

11/30

NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting

1/2

122

Europe, US, RoW

Vodobatinib (K0706) capsules

Sun Pharma Advanced Research Company Limited

Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)

08/26

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Sbraccia, Paolo

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting

N/A

100

Europe, US

Metreleptin

Aegerion Pharmaceuticals, Inc.

Generalised Lipodystrophy, Partial Lipodystrophy

10/31

ECLip Registry, NCT03553420: Registry for Patients With Lipodystrophy

Recruiting

N/A

5000

Europe, RoW

Lipodystrophy Acquired, Lipodystrophy Congenital

01/68

D'Angelillo, Rolando Maria

NCT05071105: SBRT in Early Breast Cancer in Elderly Women

Recruiting

N/A

Europe

Stereotactic Body Radiation Therapy, SBRT, Stereotaxis, Stereotactic Radiotherapy

University of Rome Tor Vergata

Breast Neoplasm Female

11/23

Cedrone, Laura

NCT05071105: SBRT in Early Breast Cancer in Elderly Women

Recruiting

N/A

Europe

Stereotactic Body Radiation Therapy, SBRT, Stereotaxis, Stereotactic Radiotherapy

University of Rome Tor Vergata

Breast Neoplasm Female

11/23

Bennane, Louiza

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites